Mephentermine

證據等級: L5

預測適應症: 4 個

Mephentermine: From Hypotension to Postural Orthostatic Tachycardia Syndrome

One-Sentence Summary

Mephentermine is a sympathomimetic amine historically used as a vasopressor for the treatment of hypotension, particularly in perioperative and anaesthetic settings. The TxGNN model predicts it may be effective for Postural Orthostatic Tachycardia Syndrome (POTS), the highest-ranked indication with a prediction score of 99.84%. However, no clinical trials and no published literature currently support this repurposing direction, and significant mechanistic concerns exist.

Quick Overview

Item	Content
Original Indication	Hypotension (vasopressor use in perioperative/anaesthetic settings)
Predicted New Indication	Postural Orthostatic Tachycardia Syndrome (POTS)
TxGNN Prediction Score	99.84%
Evidence Level	L5
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological properties, Mephentermine is a mixed adrenergic agonist with both α- and β-adrenoceptor activity. Its vasopressor effect is mediated primarily through α-adrenergic vasoconstriction and positive chronotropic/inotropic effects via β₁-adrenoceptor stimulation. These properties form the mechanistic basis for its historical use in hypotension.

POTS is characterised by an excessive compensatory sinus tachycardia upon standing, driven by inadequate venous return and orthostatic hypotension. The α-adrenergic vasoconstrictive component of Mephentermine could theoretically improve venous return and reduce orthostatic hypotension — a rationale analogous to Midodrine, the selective α₁-agonist currently used as a POTS standard of care.

However, the prediction carries an inherent mechanistic contradiction: Mephentermine’s β-adrenergic activity accelerates heart rate, which directly worsens POTS’s defining symptom — compensatory sinus tachycardia. Unlike Midodrine’s selective α₁ profile, Mephentermine’s mixed adrenergic action may amplify rather than relieve the core pathophysiology. This internal inconsistency substantially undermines the repurposing hypothesis, and no clinical data exists to resolve it.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Mephentermine is currently not marketed in India. No regulatory authorizations or product registrations are on record.

Safety Considerations

Drug Interactions (64 interactions on record; selected key examples below):

Mephentermine has 64 documented drug-drug interactions, predominantly at a Moderate severity level. A notable pattern is interaction with antidiabetic agents — Mephentermine’s sympathomimetic activity can antagonise insulin secretion and impair glucose uptake, reducing the efficacy of hypoglycaemic medications.

Interacting Drug	Severity	Clinical Relevance
Metformin	Moderate	Sympathomimetic-induced hyperglycaemia may reduce antidiabetic efficacy
Insulin glargine / aspart / detemir / degludec	Moderate	Adrenergic stimulation can antagonise insulin action and mask hypoglycaemic symptoms
Semaglutide / Dulaglutide / Lixisenatide / Albiglutide	Moderate	GLP-1 agonist efficacy may be attenuated
Canagliflozin / Dapagliflozin / Empagliflozin	Moderate	SGLT-2 inhibitor glucose-lowering effect may be reduced
Pioglitazone	Moderate	Potential attenuation of insulin-sensitising effect
Glimepiride / Chlorpropamide	Moderate	Risk of altered glycaemic control
Phentermine / Diethylpropion	Moderate	Additive sympathomimetic effects; cardiovascular risk amplified
Alogliptin / Linagliptin	Moderate	DPP-4 inhibitor efficacy potentially reduced
Acarbose	Moderate	Carbohydrate absorption modulation may interact with glycaemic response

For complete contraindications and package insert warnings, please refer to the official prescribing information, as these data were not available in the current evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score of 99.84% is high, but the evidence base is entirely absent — zero clinical trials, zero publications — placing this at Evidence Level L5 (model prediction only). More critically, the mechanistic hypothesis contains a direct internal contradiction: Mephentermine’s β-adrenergic activity would be expected to worsen the defining tachycardia of POTS, opposing the therapeutic goal. The drug is also not marketed in India, adding a significant regulatory hurdle.

To proceed, the following is needed:

Mechanistic clarification: Obtain complete MOA data from DrugBank (DG002) to formally evaluate α vs. β receptor selectivity and relevance to POTS pathophysiology
Safety baseline: Retrieve TFDA (or equivalent) package insert for full warnings and contraindications (DG001) before any clinical consideration
Preclinical evidence: Generate in vitro/in vivo data on Mephentermine’s effect on heart rate and venous capacitance in POTS models before advancing — this is the minimum scientific threshold given the mechanistic contradiction
Comparator analysis: Benchmark against Midodrine and Fludrocortisone (established POTS therapies) to identify whether a mixed adrenergic agent offers any differentiated benefit
Regulatory feasibility assessment: Given zero Indian market presence, a full registration pathway analysis would be required prior to any clinical development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.